ALR TECHNOLOGIES INC. (OTCMKTS:ALRT) Files An 8-K Regulation FD Disclosure

ALR TECHNOLOGIES INC. (OTCMKTS:ALRT) Files An 8-K Regulation FD Disclosure
ITEM 7.01REGULATION FD DISCLOSURE.

Story continues below

On October 18, 2017, ALR Technologies Inc. (the “Company”) issued a Form 8K noting that the Company provided the Securities Exchange Commission (SEC) with a letter of intention to correct its reporting deficiencies by January 26, 2018. To date the Company has filed its 2015 10K, its three 2016 10Qs and is currently undergoing its year-ended December 31, 2016 financial statement audit. To remedy its reporting deficiencies, the Company must file its 2016 10K and 2017 10Qs, which requires an extension from its original timeline. The Company has issued the SEC with an updated letter of intention to extend the period to correct its reporting deficiencies on or before February 28, 2018. The Company expects to file its 2016 10K on or before February 2, 2018.


About ALR TECHNOLOGIES INC. (OTCMKTS:ALRT)

ALR Technologies Inc. is a medical device company. The Company is engaged in providing remote monitoring and care facilitation for patients with diabetes. The Company focuses on commercializing its Heath-e-Connect System. The Company has developed a compliance monitoring system that will allow healthcare professionals to remotely monitor patient health conditions and provide patient health management. The Company’s products utilize Internet-based technologies to facilitate healthcare provider’s ability to monitor their patient’s health and ensure adherence to health maintenance activities. The Company’s Diabetes Care Facilitators and Health Data Monitors will track that data and based on clinician-approved protocols, will facilitate care interventions when patients show blood glucose readings that are out of an acceptable range or if they are failing to test their blood glucose as prescribed.

An ad to help with our costs